News | January 22, 2008

Abiomed Receives HDE Supplement Approval for Artificial Heart

January 22, 2008 - Abiomed Inc. received FDA Humanitarian Device Exemption (HDE) supplement approval on system upgrades for its AbioCor Implantable Replacement Heart (AbioCor), intended to replace the severely damaged native heart for patients who are not eligible for a transplant and have no other treatment alternative.

The AbioCor is designed to sustain the body�s circulation and extend the lives of patients who would otherwise die of heart failure, while also offering a probable benefit for a satisfactory quality of life. The AbioCor is the first completely self-contained artificial heart that may allow patients more time at home, without wires or tubes piercing through their skin. This technology provides patients with complete mobility and remote diagnostics, according to the manufacturer.

Abiomed has selected four sites to date as AbioCor Centers including: The Johns Hopkins Hospital in Baltimore, MD; Robert Wood Johnson University Hospital in New Brunswick, NJ; Texas Heart Institute at St. Luke's Episcopal Hospital in Houston, TX; and St. Vincent's Hospital in Indianapolis, IN.

HDE approval allows the AbioCor to be made available to a limited patient population, with no more than 4,000 patients receiving the technology in the United States each year. Abiomed expects to charge $250,000 per AbioCor unit in a controlled roll-out at up to five U.S. centers.

For more information: www.abiomed.com

Related Content

St. Jude Medical, HeartMate 3 LVAS, MOMENTUM 3 IDE study results, AHA Scientific Sessions 2016
News | Ventricular Assist Devices (VAD)| December 08, 2016
St. Jude Medical Inc. announced results of the MOMENTUM 3 U.S. IDE Clinical Study during a late-breaking clinical trial...
SynCardia, Chapter 11 reorganization, sale, Total Artificial Heart
News | Artificial Heart| September 13, 2016
August 29, 2016 — SynCardia Systems, manufacturer of the...
Carmat, bioprosthetic artificial heart, PIVOTAL study, first implantation, heart failure
News | Artificial Heart| September 09, 2016
Carmat announced that the first implantation of its bioprosthetic artificial heart within the framework of the PIVOTAL...
SynCardia acquired, Versa Capital Management, chapter 11
News | Business| July 07, 2016
SynCardia Systems Inc. announced that it has entered into an asset purchase agreement (“APA”) with an affiliate of...
SynCardia Total Artificial Heart, TAH-t, documentary, Retro Reports, The New York Times
News | Artificial Heart| March 24, 2016
March 24, 2016 — A new documentary produced by Retro Report for The New York Times looks at the history and
Bryan Tyo, Baylor University Medical Center, bridge to transplant, Total Artificial Heart
News | Artificial Heart| March 18, 2016
A surgical team at Baylor University Medical Center at Dallas successfully performed a heart transplant on a patient...
HeartWare, ENDURANCE2 trial, destination therapy, HVAS, HeartWare Ventricular Assist System
News | Ventricular Assist Devices (VAD)| August 11, 2015
HeartWare International Inc. announced that enrollment in the ENDURANCE2 destination therapy clinical trial has been...
News | January 30, 2015
SynCardia Systems Inc. has received U.S. Food and Drug Administration (FDA) approval to conduct a clinical study of the...
syncardia, artificial heart

SynCardia Total Artificial Heart

News | November 24, 2014
A 19-year-old woman was successfully implanted with the SynCardia temporary Total Artificial Heart and bridged to a...
Overlay Init